



E-ISSN: 2707-8353

P-ISSN: 2707-8345

IJCRO 2022; 4(2): 01-03

Received: 02-04-2022

Accepted: 07-05-2022

Dr. Rushikesh Vilas Ghongade
Junior Resident, Department
of Orthopaedics, Dr PDMC
Hospital, Amravati,
Maharashtra, India

Dr. Chaitanya Chikhale
Assistant Professor,
Department of Orthopaedics,
Dr PDMC Hospital,
Amravati, Maharashtra, India

Dr. Ganesh Pundkar
Head of Department,
Department of Orthopaedics,
Dr PDMC Hospital,
Amravati, Maharashtra, India

Dr. Rajendra Baitule
Professor, Department of
Orthopaedics, Dr PDMC
Hospital, Amravati,
Maharashtra, India

Corresponding Author:
Dr. Rushikesh Vilas Ghongade
Junior Resident, Department
of Orthopaedics, Dr PDMC
Hospital, Amravati,
Maharashtra, India

Giant cell tumor of dorsal spine: A rare case report

Dr. Rushikesh Vilas Ghongade, Dr. Chaitanya Chikhale, Dr. Ganesh Pundkar and Dr. Rajendra Baitule

DOI: <https://doi.org/10.22271/27078345.2022.v4.i2a.113>

Abstract

Giant cell tumor is a relatively rare neoplasm. In GCT the axial skeleton is extremely rarely involved. Most GCT arises in the meta-epiphyseal ends of the long bones. Peak incidence is between 30 to 40 years of age. GCT is usually classified as benign, but shows aggressive behavior and occasionally undergo transformation to malignancy. The patients with GCT in the spine often complain of the lower back pains, as the tumors primarily involve the sacrum. We report a case of an adolescent female complaining of the upper back pain with a sudden weakness of the lower extremities, later diagnosed with the GCT of the D8 vertebra. The present patient was operated using posterior lateral approach of spine and proper rehabilitation was done. Subsequent follow up revealed improvement in carrying out her daily activities.

Keywords: Neoplasm, posterior lateral approach, giant cell tumor, malignant

Introduction

Benign tumors of the bone such as giant cell tumors which have the ability to metastasize with aggressive behavior accounts for 5% of primary bone tumor [1, 2]. They have the characteristic for recurrence [3, 4]. The locations which are reported most commonly are distal femur, proximal tibia, distal radius and sacrum and rarely involve above the sacrum bone [5, 6, 7]. In spine the most common site is sacrum and rare site to involve in spine is the dorsal vertebrae. The local aggressive behavior of these lesions in the spinal column is often the reason for presentation of the patients with compressive myelopathy. Since, it is situated on the either side of neural tissues, resection of the complete mass is difficult [8, 9]. Hence, marginal or intra-lesional excision with some backup therapy is required. Modalities in past have been tried like cement injection, phenol ablation, cryotherapy and radiotherapy which have been reported in the literature [10]. With appropriate reconstruction and total spondylectomy for preservation of spinal integrity is the treatment of choice [11]. Radiation therapy can be given in cases of subtotal resection. With this background we report a rare case as follows;

Case report

A 24-year-old female presented to the outpatient department of orthopedics with chief complaints of pain in her upper back for two months, fever, and weight loss. The pain was insidious in onset and progressive in nature. The patient reported pain intensity to be 6/10, which increased to 8/10 during movement. It was a dull aching type of pain. There was no history of trauma reported by the patient. General physical examination revealed that the patient used a wheelchair with an average build and poor nourishment. Neurological examination revealed the power of 3/5 in the lower limb and 5/5 in the upper limb. The sensation of light touch, pressure, temperature, vibrations and discriminative sensations of the lower limb were decreased. We noted extensor hallucis longus muscle weakness, and the straight leg raising test was positive (knee extension 3/5 and hip flexion 3/5). The patient had reduced bowel and bladder sensations. Lower limb reflexes were present but exaggerated. We diagnosed it as compressive myelopathy of spinal origin based on the history and examination. The routine blood investigations were normal, including complete blood count, kidney function tests, and vitamin B12, vitamin D3, and folic acid levels. Serum parathyroid hormone levels were normal.

X-ray of dorsal spine (fig 1) was suggestive of expansile lytic lesion of dorsal vertebrae and destruction of the cortex. Magnetic resonance imaging of the dorsal spine (figure 2) demonstrated heterogeneous mass based on posterior elements of D8 and D10 vertebrae

and the destruction of the cortex. The lesion extended to adjacent soft tissue components involving erector spinae muscle. There was an intra-thecal extension of lesion and compression of the spinal cord at D8 vertebrae. We gave the zoledronic acid injection pre-operatively [11]. After the imaging modalities, we suspected the lesion to be giant cell tumor of the dorsal spine, causing compressive myelopathy in the D8 region. Under general anesthesia, we did en bloc resection of the mass along with wide margins using high speed burr (figure 3). We used the posterolateral approach for decompression of the spinal cord. Also, we did spinal fixation between D7 and D10 vertebrae using pedicle screws and connecting rods. Adjuvants like H₂O₂ was used in soft tissue regions. We sent the resected mass for histopathological examination, which revealed a giant cell tumor of vertebrae. (Figure 4)

Postoperatively, the neurological symptoms improved, the pain subsided, and the patient could walk with support. On follow-up at 12 weeks and 24 weeks, the patient's pain-free and overall performance were good, was walking without support and no recurrence was seen on subsequent follow up.



Fig 1: Pre- operative radiological modality x-ray of dorso-lumbar vertebrae




Fig 2: MRI of dorsal spine



Fig 3: Intra operative images during surgery




Fig 4: post op x-ray (posterior fixation using pedicle screws & connecting rod)




Fig 5: Histopathological report of the resected mass

Discussion

GCT of bone constitutes 5% of all primary bone tumors, and spine involvement is only around 1-1.5% of these cases. Middle age and slight male preponderance has been reported. Common symptoms include [12, 13]:

- Back pain.
- Neurological deficit due to spinal cord compression.
- Bladder and bowel dysfunction.
- Structural deformity of the spine.

The radiographic characteristics of spinal GCT are round or oval extrapleural mass with shell-like calcification of the marginal lesion and the absence of a mineralized matrix [14, 15]. Compared to other tumors, they involve the vertebral body, and soft-tissue involvement may be present. The most common site for so-called "benign metastasis" is the lung [16]. The histologic appearance of GCT is a uniform distribution of multinucleated giant cells against a background of round to spindle-shaped mononuclear stromal cells [17]. Enneking staging system is used to plan treatment for GCTs. This classification system divides low-grade tumors into stage 1 and high-grade tumors into stage 2 [18].

Various treatment modalities are recommended for spinal GCTs, such as surgery, radiotherapy, embolization, cryosurgery, cementation, and chemical adjuvants like H₂O₂, phenol or liquid nitrogen [17, 19-21]. Total en bloc surgical excision is the treatment of choice in long bones and the spine. Still, it is not always feasible in the spine due to the unacceptable risk of permanent neurological deficit. Prior adjuvant radiotherapy was thought to convert this low-grade tumor into a high-grade malignant tumor with a poor

prognostic outcome ^[17]. Still, with improved treatment protocols, this is not the case. However, the risk of myelitis and bone graft complications should be reserved for incomplete tumor excision and local recurrence ^[17]. Close follow-up is required to detect the recurrence of the tumor. Plain radiographs of the local site and chest are simple tools to look for any recurrent lesion. Periodic computed tomography and MRI are excellent tools to identify the recurrent lesion and plan necessary treatment ^[18, 19]. The present case report had typical symptoms of myelopathy, pain, and neurological weakness, which improved after the correct diagnosis and surgical resection. Prior to the introduction of denosumab, zoledronic acid was widely used in the management of Giant cell tumor. Denosumab and zoledronic acid both inhibit osteoclast differentiation from mononuclear cells containing osteoclast precursors. In addition, zoledronic acid also inhibits osteoclast survival, which is not seen in denosumab treatment ^[22].

We routinely use zoledronic acid pre operatively and post operatively.

Recurrence of giant cell tumor are common hence the patients need to follow up for at least 10 yrs. CT Scan of chest to detect pulmonary mets is mandatory. Treatment option for recurrence depend upon the spread of tumor. If it is localized to bone intralesional curettage and bone cementing can be done. However if it is spread to periphery then the treatment need to be supplemented with chemotherapy and radiotherapy ^[23].

Conclusion

GCT of the dorsal spine are extremely rare. Few rare cases have been reported in literature. Early diagnosis of the disease with imaging modalities and intraoperative biopsy yields better prognosis for the patient. Wide resection of the mass with spinal fixation procedure is necessary. A close follow up is mandatory to pick up both early and late complication.

References

1. Larsson SE, Lorentzon R, Boquist L. Giant-cell tumors of the spine and sacrum causing neurological symptoms. *Clin Orthop Relat Res*. 1975;111:201-11. DOI: 10.1097/00003086-197509000-00028.
2. Sanjay BK, Sim FH, Unni KK, McLeod RA, Klassen RA. Giant-cell tumours of the spine. *J Bone Joint Surg Br*. 1993;75(1):148-54. DOI: 10.1302/0301-620X.75B1.8421014.
3. Gong L, Liu W, Sun X, Sajdik C, Tian X, Niu X, *et al*. Histological and clinical characteristics of malignant giant cell tumor of bone. *Virchows Arch*. 2012;460:327-34.
4. Balke M, Schremper L, Gebert C, Ahrens H, Streitbuerger A, Koehler G, *et al*. Giant cell tumor of bone: treatment and outcome of 214 cases. *J Cancer Res Clin Oncol*. 2008;134:969-78.
5. Dahlin DC, Unni KK. General aspects and data on, cases. Springfield, IL: Charles C Thomas; Bone tumours, 1986, 507p.
6. Campanacci M, Baldini N, Boriani S, Sudanese A. Giant cell tumour of bone. *J Bone Joint Surg Am*. 1987;69:106-14.
7. Huvos AG. Bone tumors: Diagnosis, treatment and prognosis. Philadelphia: WB Saunders, 1979, 291p.
8. Turcotte RE. Giant cell tumor of bone. *Orthop Clin North Am*. 2006;37(1):35-51.
9. Kransdorf M, Murphey M. Giant cell tumor, in the imaging of bone tumors and tumor-like lesions. Davies M, Sundaram M, James S, Editors Berlin, Heidelberg, Springer-Verlag, 2009.
10. Redhu R, Poonia R. Giant cell tumor of dorsal vertebral body. *J Craniovertebr Junction Spine*. 2012;3(2):67-9. DOI: 10.4103/0974-8237.116542.
11. A) Bhojraj SY, Nene A, Mohite S, Varma R. Giant cell tumor of the spine: A review of 9 surgical interventions in 6 cas Kundu ZS, Sen R, Dhiman A, Sharma P, Siwach R, Rana P. B) Effect of Intravenous Zoledronic Acid on Histopathology and Recurrence after Extended Curettage in Giant Cell Tumors of Bone: A Comparative Prospective Study. *Indian J Orthop*. 2018 Jan-Feb;52(1):45-50. DOI: 10.4103/ortho.IJOrtho_216_17. PMID: 29416169; PMCID: PMC5791231.
12. es. *Indian J Orthop* 2007;41(2):146-50. DOI: 10.4103/0019-5413.32047.
13. Kim HS, Lee JE, Jung SS, Chon J, Yoon DH, Park YK, *et al*. Spinal Cord Injury due to the Giant Cell Tumor of the Second Thoracic Vertebra: A Case Report. *Ann Rehabil Med*. 2013;37(2):269-73. DOI: 10.5535/arm.2013.37.2.269.
14. Lucasti C, Patel D, Hawayek B, Maraschiello M, Kowalski J. Giant cell tumor of the thoracic spine causing acute paraplegia-a case report. *J Spine Surg*. 2021;7(2):208-213. DOI: 10.21037/jss-20-652.
15. Purohit S, Pardiwala DN. Imaging of giant cell tumor of bone. *Indian J Orthop*. 2007;41(2):91-6. DOI: 10.4103/0019-5413.32037.
16. Hakozaiki M, Tajino T, Yamada H, Hasegawa O, Tasaki K, Watanabe K, *et al*. Radiological and pathological characteristics of giant cell tumor of bone treated with denosumab. *Diagn Pathol*. 2014;9:111. DOI: 10.1186/1746-1596-9-111.
17. Martin C, McCarthy EF. Giant cell tumor of the sacrum and spine: series of 23 cases and a review of the literature. *Iowa Orthop J*. 2010;30:69-75.
18. Sobti A, Agrawal P, Agarwala S, Agarwal M. Giant Cell Tumor of Bone - An Overview. *Arch Bone Jt Surg* 2016;4(1):2-9. Jawad MU, Scully SP. In brief: classifications in brief: enneking classification: benign and malignant tumors of the musculoskeletal system. *Clin Orthop Relat Res* 2010 Jul;468(7):2000-2. DOI: 10.1007/s11999-010-1315-7.
19. Puri A, Agarwal M. Treatment of giant cell tumor of bone: Current concepts. *Indian J Orthop*. 2007;41(2):101-8. DOI: 10.4103/0019-5413.32039.
20. van der Heijden L, Dijkstra PD, van de Sande MA, Kroep JR, Nout RA, van Rijswijk CS, *et al*. The clinical approach toward giant cell tumor of bone. *Oncologist*. 2014;19(5):550-61.
21. Ankalkoti B, Satheesan B, Dipin J, Nizamudheen P, Sangeetha N. Retrospective Audit of Various Surgical Modalities Adopted for Giant Cell Tumor in a Rural Tertiary Cancer Center. *Indian J Surg Oncol*. 2019;10(3):489-493. DOI: 10.1007/s13193-019-00926-5.
22. Shibuya I, Takami M, Miyamoto A, *et al*. *In vitro* study of the effects of denosumab on giant cell tumor of bone: comparison with zoledronic acid. *Pathol Oncol Res*. 2019;25(1):409-419.
23. Roeder F, Timke C, Zwicker F, Thieke C, Bischof M, Debus J, *et al*. Intensity modulated radiotherapy (IMRT) in benign giant cell tumors—a single institution case series and a short review of the literature. *Radiat Oncol Lond Engl*. 2010;5:18.